Cenegermin improves corneal healing in moderate to severe neurotrophic keratitis

Topical cenegermin significantly improved corneal healing in adults with moderate to severe neurotrophic keratitis (NK) compared with vehicle, according to a study.

The analysis included 2 randomized, double-masked, vehicle-controlled trials involving 148 adults with stage 2 or 3 NK.

At 8 weeks, patients treated with cenegermin were nearly twice as likely to achieve complete corneal healing as those who received vehicle (P = 0.0001). Complete healing occurred in 72.6% of patients treated with cenegermin compared with 38.7% of those in the vehicle group.

The review found no significant difference in the risk of adverse events between treatment groups (P = 0.80).

Reference

Faroog Z, Zaidi ARZ, Tejani S. Therapeutic efficacy of cenegermin in the management of neurotrophic keratitis: a systematic review and meta-analysis of randomized controlled trials. Ther Adv Ophthalmol. 2026;18:25158414261460347. doi: 10.1177/25158414261460347. PMID: 42368179; PMCID: PMC13305801.